CD70 and neoplasm: ARGX-110, a blocking IgG1 mAb which is currently in a Phase 1b clinical trial, has been developed with enhanced antibody-dependent cellular cytotoxicity (ADCC), endowing the antibody with the ability to deplete CD70 expressing tumor cells as a mode of action additional to its ability to inhibit immune checkpoint function [21, 22].